An experimental personalized mRNA vaccine, when combined with pembrolizumab, reduced the risk of melanoma recurrence or death by 42 percent in a major phase III clinical trial, according to results presented at the European Society for Medical Oncology (ESMO) Congress in Madrid.
The study, which enrolled 1,137 patients with high-risk melanoma whose tumors had been surgically removed, marks a potential “turning point” in cancer treatment, according to the trial’s lead investigator, Georgina Long. The vaccine, known as intismeran autogene (V940), is an experimental treatment developed by Moderna in partnership with Merck—known as MSD outside the United States.
Trial Results for Intismeran and Pembrolizumab
In addition to the 42 percent reduction in the risk of recurrence or death, the study found the combination reduced the risk of the cancer spreading elsewhere in the body—distant metastasis—or death by 38 percent. The trial, INTerpath-001, provides a larger dataset than previous studies, offering stronger evidence for the efficacy of this personalized approach.
“These are very impressive results,” said Professor Alan Melcher, Professor of Translational Immunotherapy at The Institute of Cancer Research, London, who was not involved in the study. He said that while the trial is an important proof of principle, clinicians should not get ahead of the evidence.
He cautioned that researchers cannot assume this specific approach will work across all cancer types and emphasized that longer follow-up is essential to understand the effect on overall survival.
Comparison of Clinical Outcomes
| Outcome | Reduction in Risk |
|---|---|
| Recurrence or death | 42% |
| Distant metastasis or death | 38% |
The findings build on earlier phase II results presented at the AACR Annual Meeting 2023, which demonstrated improved recurrence-free survival and provided evidence that patients could benefit regardless of the status of several biomarkers. According to a report in the November 2026 issue of Sciences et Avenir, the earlier phase II trial indicated that the vaccine, when paired with immunotherapy, reduced the risk of recurrence or death by 49 percent.

Next Steps for Regulatory and Clinical Use
Manufacturers MSD and Moderna are reportedly preparing for discussions with regulatory authorities regarding the potential for future approvals. The companies are already investigating the use of personalized mRNA vaccines in a range of other cancers, including kidney, bladder, and lung cancer. For now, the treatment remains experimental and is not yet part of standard clinical practice.
Moderna, an American pharmaceutical and biotechnology company founded in 2010, specializes in RNA therapeutics and mRNA vaccines. Its name is derived from the terms “modified,” “RNA,” and “modern.” The company has developed a broad pipeline of 44 treatment and vaccine candidates, with 37 having entered clinical trials.
Its work in oncology dates back to 2014, when it created its first venture, Onkaido Therapeutics, to focus exclusively on developing mRNA-based cancer treatments. In May 2026, the company was ranked first on Time’s list of the World’s Most Impactful Companies.
Patients interested in learning more about emerging immunotherapy options or clinical trials should consult with a qualified oncologist or healthcare professional to discuss their specific medical history and potential eligibility for research studies.